Nicolas Noel

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9122940/publications.pdf

Version: 2024-02-01

45 papers	4,048 citations	471509 17 h-index	243625 44 g-index
52 all docs	52 docs citations	52 times ranked	8462 citing authors

#	Article	IF	Citations
1	Immune-related adverse events with immune checkpoint blockade: a comprehensive review. European Journal of Cancer, 2016, 54, 139-148.	2.8	1,687
2	Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia. JAMA Internal Medicine, 2021, 181, 32.	5.1	654
3	Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19. JAMA - Journal of the American Medical Association, 2021, 325, 1525.	7.4	434
4	Adipose Tissue Is a Neglected Viral Reservoir and an Inflammatory Site during Chronic HIV and SIV Infection. PLoS Pathogens, 2015, 11, e1005153.	4.7	191
5	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). Journal of Hematology and Oncology, 2021, 14, 168.	17.0	189
6	Post-acute COVID-19 syndrome. European Respiratory Review, 2022, 31, 210185.	7.1	105
7	Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation. European Respiratory Journal, 2020, 56, 2001875.	6.7	90
8	Elevated IP10 levels are associated with immune activation and low CD4+ T-cell counts in HIV controller patients. Aids, 2014, 28, 467-476.	2.2	85
9	Clinical characteristics, management and outcome of COVIDâ€19â€associated immune thrombocytopenia: a French multicentre series. British Journal of Haematology, 2020, 190, e224-e229.	2.5	68
10	Elevated Basal Pre-infection CXCL10 in Plasma and in the Small Intestine after Infection Are Associated with More Rapid HIV/SIV Disease Onset. PLoS Pathogens, 2016, 12, e1005774.	4.7	50
11	Long-Term Spontaneous Control of HIV-1 Is Related to Low Frequency of Infected Cells and Inefficient Viral Reactivation. Journal of Virology, 2016, 90, 6148-6158.	3.4	50
12	Immunologic and Virologic Progression in HIV Controllers: The Role of Viral â€œBlipsâ€•and Immune Activation in the ANRS CO21 CODEX Study. PLoS ONE, 2015, 10, e0131922.	2.5	50
13	Efficacy and Tolerance of Antiâ€“Tumor Necrosis Factor Î± Agents in Cutaneous Sarcoidosis. JAMA Dermatology, 2017, 153, 681.	4.1	46
14	A Subset of Extreme Human Immunodeficiency Virus (HIV) Controllers Is Characterized by a Small HIV Blood Reservoir and a Weak T-Cell Activation Level. Open Forum Infectious Diseases, 2017, 4, ofx064.	0.9	45
15	Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. Lancet Rheumatology, The, 2022, 4, e24-e32.	3.9	34
16	Infectious complications in patients treated with immune checkpoint inhibitors. European Journal of Cancer, 2020, 141, 137-142.	2.8	24
17	Dynamics in HIVâ€ÐNA levels over time in HIV controllers. Journal of the International AIDS Society, 2019, 22, e25221.	3.0	21
18	Multidisciplinary approach for post-acute COVID-19 syndrome: time to break down the walls. European Respiratory Journal, 2021, 58, 2101090.	6.7	18

#	Article	IF	Citations
19	Interferon-associated therapies toward HIV control: The back and forth. Cytokine and Growth Factor Reviews, 2018, 40, 99-112.	7.2	17
20	Effect of CRP value on 18Fâ€“FDG PET vascular positivity in Takayasu arteritis: a systematic review and per-patient based meta-analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 575-581.	6.4	17
21	Systemic <scp>DPP</scp>4 activity is reduced during primary <scp>HIV</scp>â€1 infection and is associated with intestinal <scp>RORC</scp>⁺<scp>CD</scp>4⁺ cell levels: a surrogate marker candidate of <scp>HIV</scp>â€induced intestinal damage. Journal of the International AIDS Society, 2018, 21, e25144.	3.0	16
22	Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach. Internal and Emergency Medicine, 2020, 15, 587-598.	2.0	16
23	Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae. Brain Communications, 2021, 3, fcab220.	3.3	16
24	Respiratory symptoms and radiological findings in post-acute COVID-19 syndrome. ERJ Open Research, 2022, 8, 00479-2021.	2.6	16
25	Immune interventions in COVID-19: a matter of time?. Mucosal Immunology, 2022, 15, 198-210.	6.0	14
26	HIV controllers: to treat or not to treat? Is that the right question?. Lancet HIV,the, 2019, 6, e878-e884.	4.7	13
27	Motivational interviewing training for medical students: A pilot pre-post feasibility study. Patient Education and Counseling, 2018, 101, 1934-1941.	2.2	12
28	Cold agglutinin disease as a new immune-related adverse event associated with anti-PD-L1sÂand its treatment with rituximab. European Journal of Cancer, 2019, 110, 21-23.	2.8	10
29	Cardiovascular Events in the French ANRS HIV Controller Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, e32-e34.	2.1	9
30	Strong ifitm1 Expression in CD4 T Cells in HIV Controllers Is Correlated With Immune Activation. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, e56-e59.	2.1	7
31	Hepatitis C virus or hepatitis B virus coinfection and lymphoma risk in people living with HIV. Aids, 2020, 34, 599-608.	2.2	7
32	Recurrent obstructive acute pyelonephritis: A rare form of Actinotignum (Actinobaculum) schaalii infection in a HIV-1 infected patient. Anaerobe, 2017, 43, 75-77.	2.1	6
33	Life-threatening Hughes-Stovin syndrome: The Yin and Yang of anticoagulation therapy. Joint Bone Spine, 2016, 83, 459-460.	1.6	5
34	Antiretroviral therapy for HIV controllers: Reasons for initiation and outcomes in the French ANRS-CO21 CODEX cohort. EClinicalMedicine, 2021, 37, 100963.	7.1	5
35	Eosinophil-rich tissue infiltrates in chronic myelomonocytic leukemia patients. Leukemia and Lymphoma, 2017, 58, 2875-2879.	1.3	3
36	Severe IgA-mediated autoimmune hemolytic anemia triggered by SARS-CoV-2 infection. Leukemia and Lymphoma, 2021, 62, 2037-2039.	1.3	3

#	Article	IF	Citations
37	Pulmonary Hypertension in Patients with Common Variable Immunodeficiency. Journal of Clinical Immunology, 2021, 41, 1549-1562.	3.8	3
38	Parvovirus B19-related peripheral nerve necrotizing vasculitis following SARS-CoV-2 infection. Revue Neurologique, 2022, 178, 158-160.	1.5	3
39	Severe ulcerative gastrointestinal toxicity following ibrutinib therapy: two case studies. Leukemia and Lymphoma, 2021, 62, 984-987.	1.3	2
40	CXCR3 and CXCR5 are highly expressed in HIVâ€1â€specific CD8 central memory TÂcells from infected patients. European Journal of Immunology, 2021, 51, 2040-2050.	2.9	2
41	Disseminated intravascular coagulation following administration of sunitinib. Molecular and Clinical Oncology, 2016, 5, 121-123.	1.0	1
42	Inflammatory demyelinating polyneuropathies and lymphoma: clues to diagnosis and therapy. Leukemia and Lymphoma, 2021, 62, 2000-2004.	1.3	1
43	Anti-Ma2 antibody encephalitis associated with Sjogren's syndrome. Revue De Medecine Interne, 2021, 42, 575-578.	1.0	1
44	Discovery of Anti-SS-A Antibodies during Stroke Investigations in Young Adults: What Impact?. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105896.	1.6	0
45	Renal involvement of lymphomas proven by kidney biopsy: report of 10 cases from a tertiary care center and comparison with the literature. International Journal of Hematology, 0, , .	1.6	0